HOPO 14-1

3,4,3-LI(1,2-HOPO)

Legal status
Legal status	Investigational
Identifiers
IUPAC name N,N′-1,4-Butanediylbis[N-[3-[[(1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]propyl]-1,6-dihydro-1-hydroxy-6-oxo-2-pyridinecarboxamide]
CAS Number	110874-36-7
PubChem CID	132648
ChemSpider	117108
UNII	R6SML525FN
ChEMBL	ChEMBL264485
CompTox Dashboard (EPA)	DTXSID301358764
Chemical and physical data
Formula	C34H38N8O12
Molar mass	750.722 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1C=CC=C(C(=O)NCCCN(C(=O)C2=CC=CC(=O)N2O)CCCCN(C(=O)C3=CC=CC(=O)N3O)CCCNC(=O)C4=CC=CC(=O)N4O)N1O
InChI InChI=1S/C34H38N8O12/c43-27-13-3-9-23(39(27)51)31(47)35-17-7-21-37(33(49)25-11-5-15-29(45)41(25)53)19-1-2-20-38(34(50)26-12-6-16-30(46)42(26)54)22-8-18-36-32(48)24-10-4-14-28(44)40(24)52/h3-6,9-16,51-54H,1-2,7-8,17-22H2,(H,35,47)(H,36,48) Key:KUWKQASGHNTJAT-UHFFFAOYSA-N

HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks. ^{[1] [2]} The active ingredient is the hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent. ^{[1] [3]} HOPO 14-1 works by selectively binding to heavy metals in the body and forming a complex that the body can naturally excrete. ^[4] The drug is also being studied as a treatment for other forms of heavy metal toxicity, including lead poisoning and exposure to gadolinium from MRI contrast agents. ^{[5] [6] [7] [8]} HOPO 14-1 was developed at Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel. Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics, a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.

References

1. "First-in-human trial of oral drug to remove radioactive contamination begins". National Institutes of Health (NIH). 2023-05-15. Retrieved 2023-05-16.
2. Roberts M (2023-05-16). "Dirty-bomb antidote: Drug trial begins in US". BBC News. Retrieved 2023-05-16.
3. Wang Q, Liu Z, Song YF, Chai Z, Wang D (March 2023). "Chelation Behaviors of 3,4,3-LI(1,2-HOPO) with Lanthanides and Actinides Implicated by Molecular Dynamics Simulations". Inorganic Chemistry. 62 (10): 4304–4313. doi:10.1021/acs.inorgchem.2c04460. PMID   36847745. S2CID   257218983.
4. Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, et al. (September 2010). "Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)". Health Physics. 99 (3): 401–407. Bibcode:2010HeaPh..99..401A. doi:10.1097/HP.0b013e3181c21273. PMC   2921233 . PMID   20699704.
5. Rees JA, Deblonde GJ, An DD, Ansoborlo C, Gauny SS, Abergel RJ (March 2018). "Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents". Scientific Reports. 8 (1) 4419. Bibcode:2018NatSR...8.4419R. doi:10.1038/s41598-018-22511-6. PMC   5849765 . PMID   29535330.
6. "This Anti-Nuclear-Contimation Pill Could Also Help MRI Patients". Lawrence Berkeley National Laboratory (Berkeley Lab). 2019-09-12. Retrieved 2023-05-29.
7. "Rebecca Abergel - Bakar Fellows Program". Bakar Fellows Program, UC Berkeley. 2021-10-21. Retrieved 2023-05-29.
8. "HOPO Therapeutics". HOPO Therapeutics, Inc. 2023-05-29. Retrieved 2023-05-29.

See also

• Diethylenetriamine pentaacetate